Malaysia’s Covid-19 vaccine supply chain just got a second track. Pharmaniaga Bhd will sell Sinovac doses directly to state governments and private companies, the pharmaceutical firm told investors Friday. Shares hit RM5.54 intraday before closing at RM5.34.
The move changes who controls the pace of vaccination. Until now, the federal government held the only keys. Pharmaniaga’s 12 million-dose contract with Putrajaya runs through July — enough to cover roughly 18 percent of the population. That obligation remains on track. But once fulfilled, the company’s Puchong plant will split its output between public contract work and new, direct buyers.
Group managing director Datuk Zulkarnain Md Eusope said the dual-track plan got clearance from the Ministry of Health. The goal is to avoid draining federal supply. “We will ensure effective provision and distribution to the private market and state governments, and it will not disrupt our existing contractual obligation with the federal government,” he told the briefing.
The stakes are concrete. Pharmaniaga currently bottles two million doses a month. Last week it filed a variation submission with the National Pharmaceutical Regulatory Agency. Approval would double monthly output to four million doses. That extra capacity is the hinge. Without it, states and companies would compete for the same limited vials the federal government already booked. With it, new buyers can secure their own quotas without slowing national coverage.
Three states have already asked for quotations: Selangor, Sarawak and Penang. All three have large populations and significant economic activity. Selangor surrounds Kuala Lumpur. Sarawak and Penang pushed for faster roll-outs earlier in the pandemic. Corporate buyers are lining up too — especially glove makers and oil-and-gas producers. These are firms classified as essential during lockdowns. Their workers need shots to keep factories and platforms running.
This is not a small adjustment. It is a structural shift in Malaysia’s vaccine logistics. The federal government remains the dominant purchaser, but it is no longer the only one. States with political will and budget can move ahead of the national queue. Companies that want to protect their workforce can buy direct. The Ministry of Health signed off, which suggests the government sees this as acceleration, not fragmentation.
The risk is real. If NPRA approves the output doubling, Pharmaniaga can serve both masters. If not, the company must choose. Federal contract first — that is the law. State and corporate buyers would then wait for surplus capacity. That could mean delays for Selangor, Sarawak and Penang. It could mean glove makers and oil producers see their timelines slip.
Zulkarnain framed the plan as a way to hit broader coverage faster. The numbers back him. Twelve million federal doses cover 18 percent of the population. Additional state and corporate purchases push that share higher without costing Putrajaya a ringgit more. The company’s Puchong facility is the bottleneck. A yes from NPRA widens it.
Pharmaniaga’s share price reaction tells its own story. Investors saw the announcement and bought. The stock hit RM5.54 before settling at RM5.34. The market read the same facts: new revenue streams, expanded production, government backing. That is a vote of confidence in the plan’s viability.
What happens next depends on regulators and demand. The variation submission is pending. States are circling. Companies are ready to sign. The federal contract finishes in July. After that, the plant’s capacity belongs to whoever pays first. That could be Putrajaya again, or it could be Shah Alam, Kuching and George Town. Or it could be Top Glove and Petronas. The queue is forming.
